Nkarta (NKTX) Other Gross PP&E Adjustments (2019 - 2026)
Nkarta's quarterly Other Gross PP&E Adjustments came in at $61.8 million in Q1 2026, up 2.63% year-on-year from $60.2 million in Q1 2025, and up 9.95% quarter-over-quarter from $56.2 million in Q4 2025.
Nkarta has reported Other Gross PP&E Adjustments for 8 years, with the latest figure at $61.8 million in Q1 2026.
- For the quarter ending Q1 2026, Other Gross PP&E Adjustments rose 2.63% year-over-year to $61.8 million; the trailing twelve-month figure through Mar 2026 stood at $61.8 million (up 2.63% YoY), and the FY2025 full-year result was $56.2 million, up 3.42% from the prior year.
- Other Gross PP&E Adjustments for Q1 2026 stood at $61.8 million, up from $56.2 million in the prior quarter.
- The five-year high for Other Gross PP&E Adjustments was $62.2 million in Q3 2025, with the low at -$62.0 million in Q1 2022.
- Average Other Gross PP&E Adjustments over 5 years is $33.2 million, with a median of $53.1 million recorded in 2024.
- Peak annual rise in Other Gross PP&E Adjustments reached 769.39% in 2022, while the deepest fall reached 17468.07% in 2022.
- Tracing NKTX's Other Gross PP&E Adjustments over 5 years: stood at $18.4 million in 2022, then surged by 151.76% to $46.4 million in 2023, then grew by 17.17% to $54.4 million in 2024, then increased by 3.42% to $56.2 million in 2025, then rose by 9.95% to $61.8 million in 2026.
- The last three Other Gross PP&E Adjustments figures came in at $61.8 million (Q1 2026), $56.2 million (Q4 2025), and $62.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 61.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61.82 Mn |
| Mar 31, 2026 | 61.82 Mn |
| Dec 31, 2025 | 56.23 Mn |
| Dec 31, 2025 | 56.23 Mn |
| Sep 30, 2025 | 62.17 Mn |
| Sep 30, 2025 | 62.17 Mn |
| Jun 30, 2025 | 60.74 Mn |
| Jun 30, 2025 | 60.74 Mn |
| Mar 31, 2025 | 60.24 Mn |
| Mar 31, 2025 | 60.24 Mn |
| Dec 31, 2024 | 54.37 Mn |
| Dec 31, 2024 | 54.37 Mn |
| Sep 30, 2024 | 55.98 Mn |
| Sep 30, 2024 | 55.98 Mn |
| Jun 30, 2024 | 54.39 Mn |
| Jun 30, 2024 | 54.39 Mn |
| Mar 31, 2024 | 53.11 Mn |
| Mar 31, 2024 | 53.11 Mn |
| Dec 31, 2023 | 46.40 Mn |
| Dec 31, 2023 | 46.40 Mn |
| Sep 30, 2023 | 46.61 Mn |
| Sep 30, 2023 | 46.61 Mn |
| Jun 30, 2023 | 42.48 Mn |
| Jun 30, 2023 | 42.48 Mn |
| Mar 31, 2023 | 30.82 Mn |
| Mar 31, 2023 | 30.82 Mn |
| Dec 31, 2022 | 18.43 Mn |
| Dec 31, 2022 | 18.43 Mn |
| Sep 30, 2022 | -32.63 Mn |
| Sep 30, 2022 | -32.63 Mn |
| Jun 30, 2022 | -44.66 Mn |
| Jun 30, 2022 | -44.66 Mn |
| Mar 31, 2022 | -62.00 Mn |
| Mar 31, 2022 | -62.00 Mn |
| Dec 31, 2021 | 2.12 Mn |
| Dec 31, 2021 | 2.12 Mn |
| Sep 30, 2021 | 5.78 Mn |
| Sep 30, 2021 | 5.78 Mn |
| Jun 30, 2021 | 1.40 Mn |
| Jun 30, 2021 | 1.40 Mn |
| Mar 31, 2021 | 357,000.00 |
| Mar 31, 2021 | 357,000.00 |
| Dec 31, 2020 | 1.40 Mn |
| Dec 31, 2020 | 1.40 Mn |
| Sep 30, 2020 | 1.57 Mn |
| Sep 30, 2020 | 1.57 Mn |
| Jun 30, 2020 | -339,259.00 |
| Jun 30, 2020 | -339,259.00 |
| Dec 31, 2019 | -3.42 Mn |
| Dec 31, 2019 | -3.42 Mn |